Multiple System Atrophy clinical trials at University of California Health
13 in progress, 4 open to eligible people
YA-101 in Patients With Multiple System Atrophy
open to eligible people ages 30 years and up
This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.
at UCLA
Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study
open to eligible people ages 30 years and up
The primary objective of the study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the study is to evaluate specific efficacy parameters of TEV-56286. Another secondary objective is to evaluate the safety and tolerability of TEV-56286. The planned study period per participant is 56 weeks including a screening period (up to 4 weeks), a 48-week double-blind treatment period, and a follow-up visit (approximately 4 weeks after the end of the double-blind treatment period). The study duration will be approximately 27 months.
at UCLA
Lu AF82422 in Participants With Multiple System Atrophy (MSA)
open to eligible people ages 40-75
The main goal of this trial is to evaluate the efficacy and safety of Lu AF82422 for the treatment of participants with Multiple System Atrophy (MSA).
at UCSF
North American Prodromal Synucleinopathy Consortium Stage 2
open to eligible people ages 18 years and up
This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
at UCLA
ONO-2808 in Patients With Multiple System Atrophy
Sorry, in progress, not accepting new patients
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in patients with MSA.
at UCLA
Lu AF82422 in Participants With Multiple System Atrophy
Sorry, in progress, not accepting new patients
To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.
at UCSD UCSF
GDNF Gene Therapy for Multiple System Atrophy
Sorry, in progress, not accepting new patients
The objective of this randomized, double-blinded, placebo-controlled Phase 1 investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a possible or probable diagnosis of Multiple System Atrophy.
at UC Irvine
Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
Sorry, in progress, not accepting new patients
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This study includes 4 periods: Screening, open label, randomized withdrawal, and long-term treatment extension (LTE).
at UCLA UCSD
Parkinson's And Zoledronic Acid
Sorry, in progress, not accepting new patients
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 2650 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.
at UC Davis UC Irvine UCLA UCSF
AB-1005 Long-Term Follow-up Study
Sorry, not yet accepting patients
This is an observational, long term, follow-up study for participants with Parkinson's disease (PD) or Multiple System Atrophy-Parkinsonian subtype (MSA-P) who participated in prior interventional studies with AB-1005. It is intended to better understand the long-term safety of AB-1005, how well tolerated it is and how long lasting the effects are.
at UCSF
Automated Imaging Differentiation of Parkinsonism
Sorry, in progress, not accepting new patients
The purpose of this study is to test the performance of the AID-P across 21 sites in the Parkinson Study Group. Each site will perform imaging, clinical scales, diagnosis, and will upload the data to the web-based software tool. The clinical diagnosis will be blinded to the diagnostic algorithm and the imaging diagnosis will be compared to the movement disorders trained neurologist diagnosis.
at UCSD UCSF
North American Prodromal Synucleinopathy Consortium
Sorry, accepting new patients by invitation only
This study will enroll participants with idiopathic rapid eye movement (REM) sleep behavior disorder (RBD), for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
at UCLA
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
Sorry, in progress, not accepting new patients
The objective of this study is to describe disease progression in study participants diagnosed with early Parkinson's Disease or Multiple System Atrophy - Parkinsonian Type up to 18 months as delineated by clinical and biochemical parameters.
at UC Irvine
Our lead scientists for Multiple System Atrophy research studies include Susan L. Perlman, MD Danielle N. Thordarson, MD Alon Avidan, MD, MPH.
Last updated: